Compass Therapeutics' (CMPX) Buy Rating Reiterated at D. Boral Capital

Compass Therapeutics (NASDAQ:CMPX - Get Free Report)'s stock had its "buy" rating restated by D. Boral Capital in a research note issued on Monday,Benzinga reports. They presently have a $32.00 target price on the stock.

A number of other research firms have also recently commented on CMPX. HC Wainwright lifted their price target on Compass Therapeutics from $10.00 to $24.00 and gave the stock a "buy" rating in a report on Friday, April 4th. Jefferies Financial Group increased their price target on Compass Therapeutics from $7.00 to $8.00 and gave the company a "buy" rating in a research note on Monday, February 10th. Leerink Partnrs raised shares of Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 1st. Leerink Partners upgraded shares of Compass Therapeutics from a "market perform" rating to an "outperform" rating and upped their price objective for the company from $4.00 to $6.00 in a report on Wednesday, April 2nd. Finally, Piper Sandler began coverage on shares of Compass Therapeutics in a research note on Wednesday, February 19th. They set an "overweight" rating and a $12.00 target price for the company. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $13.38.

Compass Therapeutics Stock Performance

NASDAQ CMPX traded up $0.09 during trading hours on Monday, hitting $2.07. 950,418 shares of the company traded hands, compared to its average volume of 869,816. The stock has a market capitalization of $286.25 million, a price-to-earnings ratio of -5.59 and a beta of 1.40. Compass Therapeutics has a twelve month low of $0.77 and a twelve month high of $4.08. The business's 50-day moving average is $2.28 and its 200-day moving average is $2.09.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). Analysts predict that Compass Therapeutics will post -0.36 EPS for the current year.

Insider Buying and Selling at Compass Therapeutics

In other news, Director Carl L. Gordon sold 3,571,428 shares of the company's stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total transaction of $5,678,570.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jonathan Anderman purchased 20,000 shares of the firm's stock in a transaction that occurred on Monday, April 7th. The stock was bought at an average price of $1.54 per share, for a total transaction of $30,800.00. Following the transaction, the insider now directly owns 21,000 shares of the company's stock, valued at $32,340. This trade represents a 2,000.00 % increase in their position. The disclosure for this purchase can be found here. Insiders own 28.50% of the company's stock.

Institutional Trading of Compass Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Tower Research Capital LLC TRC raised its position in Compass Therapeutics by 298.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company's stock valued at $25,000 after purchasing an additional 12,917 shares in the last quarter. Independent Advisor Alliance bought a new position in shares of Compass Therapeutics in the 4th quarter valued at $26,000. BNP Paribas Financial Markets acquired a new position in shares of Compass Therapeutics during the 4th quarter worth $27,000. XTX Topco Ltd bought a new stake in shares of Compass Therapeutics during the 3rd quarter worth $37,000. Finally, Mariner LLC acquired a new stake in Compass Therapeutics in the fourth quarter valued at about $30,000. Institutional investors own 68.43% of the company's stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.